

STRATEGY DINNER

Seamless global strategy for NCE development and API supply chain by optimizing technology, providing collective expertise, and reducing the delivery time and cost – an unmet need

The “heart of drug development” is to employ innovative technologies and collaborations across the globe, to assemble a powerful Drug Development Engine to accelerate candidates from drug discovery, PRD, scale-up through commercialization. The best way to increase the valuation of drug discovery and development pipeline and company’s portfolio is to accelerate their milestones, reduce costs while maintaining quality. Today’s CDMO industry is lacking a unique collective expertise in one place, utilizing ground-breaking technologies for the synthesis of architecturally complex molecules that can intercept any molecule, at any stage of development. Ultimately the know-how of phase appropriate execution, ‘shaving’ months off the development cycle time and a “one stop shop” of delivery of entire CMC management is an unmet need.

OCT
12

WEDNESDAY

Radisson BLU



Radisson Blu Hotel Zurich Airport

AGENDA

17:00 - 18:00	Registration, Networking & Cocktails
18:00 - 18:15	Welcome & Introductions Swapan Bhattacharya, Managing Director, TCG Lifesciences Pvt. Ltd. Sanjoy Kumar Mahanty, Ph.D, VP, Business Development, TCG Lifesciences Pvt. Ltd.
18:15 - 19:15	Roundtable Discussion on: Big Pharma training with Biotech mentality to “Accelerate Molecules to Medicines” <ul style="list-style-type: none">• Solving complicated CMC problems for NCEs adopting “First Time Right” techniques for First in Human studies• Reducing timelines by utilizing optimized “Drug Development Engine”• Leveraging innovative technologies embedded in Process Research and Development for API• Utilization of dynamic cost structure model• Tapping global resource pool• US management oversight operation• 24 hr/day for solving problems and deliveries• Smooth tech transfer for API in a global setting• Implementing collective expertise of globally based scientists, scientific project managers and engagement with client-based approach• Maintaining transparency and IP protection Joseph D. Armstrong, III, Ph.D, COO, TCG GreenChem, Inc. (NJ & VA, USA)
19:15 - 20:30	Dinner
20:30 - 21:30	Roundtable Discussion: Continue the topic Big-Pharma training with Biotech mentality to “Accelerate Molecules to Medicines” Subho Roy, Ph.D, Vice President - Business Head, Clinivent Research Pvt. Ltd, A 100% subsidiary of TCG Lifesciences
21:30 - 22:00	Closing Remarks, Coffee & Cognacs Vishal Rajput, Ph.D, Vice President, Business Development, TCG Lifesciences Pvt. Ltd. Gopal Sirasani, Ph.D, AVP, Business Development, TCG GreenChem

KEY OPINION LEADERS



Swapan Bhattacharya - Managing Director, TCG Lifesciences Pvt. Ltd.

Swapan Bhattacharya is the Managing Director of TCG Lifesciences (TCGLS) and is responsible for the executive leadership and overall management of the company. He co-founded TCGLS in 2001 and has taken the Company to a global leadership position in the research services space. He is also a key member of the Governing Council of the TCG Centers for Education and Research in Science and Technology, a not-for-profit institute in the process of spawning multiple centers of excellence in the frontier fields of translational neuroscience and oncology, AI and quantum computing. He has been associated with the TCG Group since 1995 and has spearheaded the group's investments in India and its entry into life sciences domains from 1998. His professional career has spanned across the globe for about 40 years. Prior to joining the Group, he has held positions with PaineWebber Inc. as Senior Vice President and as Consultant to the US Nuclear Regulatory Commission. Over the years, he has held leadership committee positions in US India Business Council, FICCI, AMCHAM and Assocham; several board positions; and received excellence awards. He holds a bachelor's degree in engineering from the Indian Institute of Technology, Kharagpur, a master's degree from the Virginia Polytechnic Institute and State University, U.S.A and an MBA from Kellogg School of Management, Northwestern University, U.S.A. He received the Lester Cunningham Award for academic excellence at Northwestern.



Sanjoy Kumar Mahanty, Ph.D - VP, Business Development, TCG Lifesciences Pvt. Ltd.

Dr. Sanjoy Kumar Mahanty is part of the core business development, account management, marketing & sales team in the USA. Dr. Mahanty has twenty-five years of expertise in scientific research, and extensive leadership experience in drug discovery & development process. Dr. Mahanty has been associated with TCG Lifesciences for over eight years. He has been highly successful in penetrating CRO/CDMO markets globally, and proven track-record in establishing the new business, and maintaining existing clients. He holds a bachelor's degree from Utkal University, and a master's of sciences (MSc) & PhD degree in Biochemistry from Jawaharlal Nehru University, New Delhi, India. Dr. Mahanty completed his Post-Doctoral Research Experience from Harvard Medical School, Boston, and University of North Carolina, Chapel Hill, USA. He has eighteen co-authored peer reviewed publications including one in the highly reputed journal CELL, one book chapter, and ten shared patents to his credit.



Joseph D. Armstrong, III, Ph.D - COO, TCG GreenChem, Inc. (NJ & VA, USA)

Dr. Armstrong is a high energy scientific and executive leader with 28 years of experience at Merck & Co., Inc. in Process Research, Formulation Development and Project Management with deep knowledge and experience of all drug discovery and development processes to support IND to NDA filings. As the Merck Preclinical Integration Lead (Process R&D, Formulation R&D, DMPK, Safety Assessment, and Clinical Supplies) for the merger with Schering Plough, created a multidisciplinary organization that leveraged development knowledge to accelerate identification of Preclinical Candidates and their rapid entry into the clinic and beyond. He led the cross-functional team that filed the drug “Januvia” for the treatment of type II diabetes in less than 4 years by executing new green and sustainable technologies and strategies. He led the Process R&D Team that discovered the novel and the preparation of Sitagliptin, the active ingredient in “Januvia”. This team received the Thomas Edison award, the EU IChemE Aztra-Zeneca Award for Green Chemistry and Engineering and the US Presidential Green Chemistry Challenge Award.



Subho Roy, Ph.D - Vice President - Business Head, Clinivent Research Pvt. Ltd, A 100% subsidiary of TCG Lifesciences

Dr. Subho Roy joined the group in 2002 and has been one of the key leadership members responsible for the growth of the company. He holds a Ph.D degree from Indian Institute of Chemical Technology, working with Dr. A.V.Rama Rao, on synthesis of natural products of biological importance and subsequently spent few years at the University of Kansas, Lawrence, USA, working with Dr. Gunda Georg for his post-doctoral studies. He has more than 20 years of industrial experience of progressing small molecules coming out of R&D through various phases of development and taking them all the way to commercialization. He is a specialist in new process development, optimization and various other aspects of CMC. Dr. Roy has several publications to his credit and holds several European and US patents. He has played a key role in conceptualizing and designing of the manufacturing facility, “Clinivent Research Pvt. Ltd.”, a 100% subsidiary of TCG Lifesciences, which has successfully completed US FDA inspection.



Vishal Rajput, Ph.D - Vice President, Business Development, TCG Lifesciences Pvt. Ltd.

Dr. Vishal Rajput holds Masters in Chemistry from IIT Roorkee, he is a Ph.D in Medicinal Chemistry from CDRI Lucknow, and a Post Doctorate from Lund University, Sweden and University of Alberta, Canada. He also holds PG diploma in patent Law from NALSAR Law University, Hyderabad. He is a seasoned techno-commercial professional with experience in Pharma/Life science industries spans across Business Development (CDMO), API-Sales, Project and Portfolio Management and in R&D from top-tier pharma and biotech companies like Syngene Int Ltd, Merck and Sigma-Aldrich etc. His last assignment was with Shilpa Medicare Ltd. as Head of Global CDMO Substance - Drug Substance and Drug Product. He also has cross value chain expertise and Business Development experience covering discovery, development and manufacturing services for small and large molecules (ADC, NCE, Carbohydrates, Polymer and peptide) API for global Innovator and Generic companies.



Gopal Sirasani, Ph.D - AVP, Business Development, TCG GreenChem

Dr. Gopal Sirasani is the Associate Vice President, CDMO Business Development & Technical Operations of TCG GreenChem. He is responsible for key account management, marketing, and sales operations. He has been highly successful in establishing new business collaborations between biotech companies and TCG GreenChem/TCG Lifesciences. Dr. Sirasani is heavily involved in tracking the customer projects for CMC development, in terms of route scouting, process development, scale-up operations and cGMP/non-GMP campaigns to deliver for preclinical and clinical needs of the clients. Dr. Sirasani received his bachelor's in Chemical Technology, Masters in Drugs and Pharmaceuticals, Ph.D. in Synthetic Organic Chemistry at Temple University, Philadelphia, and Post-Doctoral training at Harvard University. In total, he has 18 years of academic and industrial experience.

At TCG, we address these needs with a proven strategy utilizing the following inherent strengths:

- Top tier and experienced people from big-Pharma
- High end technology platforms and science, like continuous chemistry, catalysis
- Large PRD group working across the globe
- Operational synergies amongst group companies
- Trust-based client relations and depth of engagement spanning two decades
- World class facilities and infrastructure

We deliver integrated end-to-end solutions to the global life sciences' industries.



IN PARTNERSHIP WITH:



Why Book Your V.I.P Seat Now?

- ✓ Be amongst 10-15 Industry thought leaders from a mix of large Pharmaceutical Institutions ensuring you are given ample opportunity to raise questions and contribute from a strategic perspective.
- ✓ Wine, dine and network with industry leaders who face common challenges in 60-minute roundtable discussions that enable you to share ideas and lessons learned.
- ✓ Facilitated by expert moderators, these sessions provide a valuable dialogue with peers on current challenges and topical issues.
- ✓ No media, marketing or press, just pure and honest discussion to help solve your key strategic challenges for the next 3-9 months.



Contact Details:
GEN AMORILLO

@ ga@proventainternational.com

+1 (617) 4315492 ext 327

www.proventainternational.com